186 related articles for article (PubMed ID: 35405351)
21. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
22. An extensive review on antifungal approaches in the treatment of mucormycosis.
Chaudhari HS; Palkar OS; Abha Mishra KM; Sethi KK
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23417. PubMed ID: 37345721
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
[TBL] [Abstract][Full Text] [Related]
24. Clinical and Mycologic Characteristics of Emerging Mucormycosis Agent Rhizopus homothallicus.
Rudramurthy SM; Singh S; Kanaujia R; Chaudhary H; Muthu V; Panda N; Pandey A; Thakur S; Kaur H; Ghosh A; Agarwal R; Chakrabarti A
Emerg Infect Dis; 2023 Jul; 29(7):1313-1322. PubMed ID: 37347535
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
[TBL] [Abstract][Full Text] [Related]
26. Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
Luo G; Gebremariam T; Lee H; Edwards JE; Kovanda L; Ibrahim AS
Antimicrob Agents Chemother; 2014; 58(4):2450-3. PubMed ID: 24492363
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with posaconazole in patients with invasive mucormycosis: a case series.
González-Ramos MM; Bertrán-Pasarell J; Guiot H; Soto R; Santana J; Amador R; Conde A
P R Health Sci J; 2008 Dec; 27(4):328-32. PubMed ID: 19069358
[TBL] [Abstract][Full Text] [Related]
28. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents.
Chitasombat MN; Kontoyiannis DP
Curr Opin Infect Dis; 2016 Aug; 29(4):340-5. PubMed ID: 27191199
[TBL] [Abstract][Full Text] [Related]
29. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran.
Pakdel F; Ahmadikia K; Salehi M; Tabari A; Jafari R; Mehrparvar G; Rezaie Y; Rajaeih S; Alijani N; Barac A; Abdollahi A; Khodavaisy S
Mycoses; 2021 Oct; 64(10):1238-1252. PubMed ID: 34096653
[TBL] [Abstract][Full Text] [Related]
30. Role of Amphotericin B in the Treatment of Mucormycosis.
Sachdeva A; Targhotra M; Chauhan MK; Chopra M
Curr Pharm Des; 2024; 30(1):1-9. PubMed ID: 38178658
[TBL] [Abstract][Full Text] [Related]
31. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
Shirley M; Scott LJ
Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review.
Meena DS; Kumar D; Bohra GK
J Mycol Med; 2023 Mar; 33(1):101332. PubMed ID: 36270213
[TBL] [Abstract][Full Text] [Related]
33. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn).
Salmanton-García J; Seidel D; Koehler P; Mellinghoff SC; Herbrecht R; Klimko N; Ráčil Z; Falces-Romero I; Ingram P; Benítez-Peñuela MÁ; Rodríguez JY; Desoubeaux G; Barać A; García-Vidal C; Hoenigl M; Mehta SR; Cheng MP; Klyasova G; Heinz WJ; Iqbal N; Krause R; Ostermann H; Penack O; Schalk E; Sheppard DC; Willinger B; Wisplinghoff H; Vehreschild JJ; Cornely OA; Vehreschild MJGT;
J Antimicrob Chemother; 2019 Nov; 74(11):3315-3327. PubMed ID: 31393591
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients.
Barg AA; Malkiel S; Bartuv M; Greenberg G; Toren A; Keller N
Pediatr Blood Cancer; 2018 Oct; 65(10):e27281. PubMed ID: 29932282
[TBL] [Abstract][Full Text] [Related]
35. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
36. Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature.
Pomorska A; Malecka A; Jaworski R; Radon-Proskura J; Hare RK; Nielsen HV; Andersen LO; Jensen HE; Arendrup MC; Irga-Jaworska N
Mycopathologia; 2019 Feb; 184(1):81-88. PubMed ID: 30039238
[TBL] [Abstract][Full Text] [Related]
37. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules.
Dieringer TD; Schaenman JM; Davis MR
J Antimicrob Chemother; 2022 Apr; 77(5):1417-1423. PubMed ID: 35174391
[TBL] [Abstract][Full Text] [Related]
38. Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.
Mezhir JJ; Mullane KM; Zarling J; Satoskar R; Pai RK; Roggin KK
Surg Infect (Larchmt); 2009 Oct; 10(5):447-51. PubMed ID: 19485785
[TBL] [Abstract][Full Text] [Related]
39. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
Seidel D; Simon M; Sprute R; Lubnow M; Evert K; Speer C; Seeßle J; Khatamzas E; Merle U; Behrens C; Blau IW; Enghard P; Haas CS; Steinmann J; Kurzai O; Cornely OA
Mycoses; 2022 Jan; 65(1):103-109. PubMed ID: 34655486
[TBL] [Abstract][Full Text] [Related]
40. A mucormycosis case in a cirrhotic patient successfully treated with posaconazole and review of published literature.
Lin SY; Lu PL; Tsai KB; Lin CY; Lin WR; Chen TC; Chang YT; Huang CH; Chen CY; Lai CC; Chen YH
Mycopathologia; 2012 Dec; 174(5-6):499-504. PubMed ID: 22744722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
